As of 2021, the prevalence of diabetics in the UK totaled 8.2 percent. Type 2 diabetes, highly related to unhealthy lifestyle choices, such as the overconsumption of sugar and a lack of exercise, as well as aging, affects more individuals than type 1 diabetes. Between 2023 and 2024, over 3.5 million people in England were registered with type 2 diabetes, while almost 277 thousand had type 1. Type 1 diabetes Between 2023 and 2024, most people registered with type 1 diabetes in England were aged 40 years and younger, with 44.7 percent. In 2021, the UK was the European country with the second-highest number of children and adolescents with type 1 diabetes after Germany, with over 31,600 cases. Treatment The NHS in the UK provides nine care processes annually to people with diabetes. Blood pressure checks, cholesterol monitoring, and foot surveillance are among those. Figures show that almost half of individuals in England with type 2 diabetes received all nine care processes between 2022 and 2023. This figure totaled 37 percent in the case of patients with type 1 diabetes. The same trend could be observed in Wales in 2021/22, where the share of type 2 diabetics receiving all care processes was double the type 1 patients.

Type 2 diabetes is a condition that affects the amount of sugar in a person’s bloodstream and causes it to become too high. This type of diabetes can be caused by risk factors such as obesity and inactivity and, as shown in this figure, type 2 diabetes is more common among older individuals. Between 2023 and 2024, of those registered with type 2 diabetes in England, **** percent were aged between 40 and 64 years. Increasing prevalence of diabetes in England Between 2023 and 2024, there were over *** million people in England who were registered as diabetics. The number of individuals registered with diabetes in England has increased year-on-year since 2008. The vast majority of those registered with diabetes in England are diagnosed with type 2 diabetes, with over *** million, while approximately *** thousand living with type 1 diabetes. Diabetes medication By far the most used drug in England for the treatment of diabetes was metformin hydrochloride with over ** million items used in 2022 alone. Additionally, already in 2018 approximately **** percent of all prescribed drugs in primary care in England were for the treatment of diabetes. The share of prescribed diabetes drugs has steadily increased since 2005.

The National Diabetes Audit (NDA) provides a comprehensive view of diabetes care in England and Wales. It measures the effectiveness of diabetes healthcare against National Institute for Health and Care Excellence (NICE) Clinical Guidelines and NICE Quality Standards. This NICE guidance is based on evidence that regular systematic review of people with diabetes and achievement of glucose, blood pressure and cardiovascular risk standards maintains health and reduces long term complications.

The National Diabetes Audit (NDA) is part of the National Clinical Audit and Patient Outcomes Programme (NCAPOP) which is commissioned by the Healthcare Quality Improvement Partnership (HQIP) and funded by NHS England. The NDA is managed by NHS Digital in partnership with Diabetes UK. The National Diabetes Audit (NDA) provides a comprehensive view of diabetes care in England and Wales. It measures the effectiveness of diabetes healthcare against NICE Clinical Guidelines and NICE Quality Standards. The NDA supports improvement in the quality of diabetes care by enabling participating NHS services and organisations to: Assess local practice against NICE guidelines. Compare their care, and care outcomes, with similar services and organisations. Identify gaps or shortfalls that are priorities for improvement. Identify and share best practice and provide a comprehensive national picture of diabetes care and outcomes in England and Wales. This data release includes the care process and treatment target measurements for 2020-21 (1st January 2020 – 31st March 2021). Data were collected during May and June 2021. The national report, scheduled for 2022, will contain commentary on the audit findings and recommendations. We will communicate to users when the publication date for this report has been finalised. Note: An issue was identified with the Wales data release whereby structured education offered data was underreported. This has now been corrected in the version of the file available on this webpage.

The worksheets include data for all Integrated Care Boards (ICBs), Primary Care Networks (PCNs) and GP practices in England within the May 2023 extraction of NDA data (January 2022 to March 2023 data). These data undergo further validation processes at the end of each audit year when data from specialist services are added in, at which point the data are considered to comprise the full annual dataset to be used in the annual NDA publications. Data for Local Health Boards (LHBs) in Wales and specialist diabetes services in England are not included in the quarterly publications. Their 2022-23 data (for the full audit period January 2022 to March 2023) will be reported in the full audit period data release scheduled for late 2023. Disclosure control has been applied to mitigate the risk of patient identification. Zeros are reported, and all numbers are rounded to the nearest 5, unless the number is 1 to 7, in which case it is rounded to ‘5’. This allows for more granular data to be made available, and also for data for all GP practices to be made available.

According to Cognitive Market Research, the global Implantable Insulin Pumps Market size will be USD 3862.4 million in 2025. It will expand at a compound annual growth rate (CAGR) of 9.70% from 2025 to 2033.

North America held the major market share for more than 40% of the global revenue with a market size of USD 1429.09 million in 2025 and will grow at a compound annual growth rate (CAGR) of 7.5% from 2025 to 2033.
Europe accounted for a market share of over 30% of the global revenue with a market size of USD 1120.10 million.
APAC held a market share of around 23% of the global revenue with a market size of USD 926.98 million in 2025 and will grow at a compound annual growth rate (CAGR) of 11.7% from 2025 to 2033.
South America has a market share of more than 5% of the global revenue with a market size of USD 146.77 million in 2025 and will grow at a compound annual growth rate (CAGR) of 8.7% from 2025 to 2033.
Middle East had a market share of around 2% of the global revenue and was estimated at a market size of USD 154.50 million in 2025 and will grow at a compound annual growth rate (CAGR) of 9.0% from 2025 to 2033.
Africa had a market share of around 1% of the global revenue and was estimated at a market size of USD 84.97 million in 2025 and will grow at a compound annual growth rate (CAGR) of 9.4% from 2025 to 2033.
Open-loop Insulin Pump category is the fastest growing segment of the Implantable Insulin Pumps industry

Market Dynamics of Implantable Insulin Pumps Market

Key Drivers for Implantable Insulin Pumps Market

Rising Incidence of Vision-related Conditions to Boost Market Growth

The market for implantable insulin pumps is anticipated to develop in the future due to the increase in diabetes cases. Because of either insufficient insulin synthesis or inefficient cell utilization of insulin, diabetes is a chronic illness in which the body has difficulty regulating blood sugar levels. An aging population, poor diets, a lack of physical activity, and increased obesity rates are some of the causes contributing to the rise in diabetes incidence. With the help of an implanted insulin pump, blood glucose levels can be stabilized, injection frequency can be decreased, and overall diabetes control and quality of life can be enhanced. For instance, a report released in May 2024 by Diabetes UK, a UK-based organization for people with diabetes, states that over 5.6 million people in the UK have diabetes, representing a 167,822 rise in cases between 2022–2023. Thus, the market for implantable insulin pumps is expanding as a result of the rise in diabetes cases.

https://www.diabetes.org.uk/about-us/about-the-charity/our-strategy/statistics#:~:text=We%20estimate%20that%20more%20than,living%20with%20overweight%20or%20obesity.

Growing Diabetes Incidence and Quick Technological Developments to Boost Market Growth

The Implantable Insulin Pumps market is seeing a growing number of businesses concentrate on introducing smart infusion pumps. Health monitoring gadgets are increasingly using wireless technology, which improves data processing, communication, and user-friendliness. By using Bluetooth or another cellular connection, wireless technology allows data to be transferred from the device to a smartphone or other wireless device for processing. This data can then be utilized for research purposes and to assess a person's health. The market grows as a result. In addition, the market is growing as a result of the rising number of acquisitions by market participants. In 2021, for example, the Alfred E. Mann Foundation sold its implanted infusion pump technology to Medtronic, a U.S.-based medical device firm. The purpose of the acquisition was to improve the way insulin is delivered to individuals with type 1 diabetes. Medical technologies such as implanted infusion pumps are being introduced by the Alfred E. Mann Foundation, a scientific research organization based in the United States. Consequently, this element accelerates market expansion.

https://www.fiercebiotech.com/medtech/medtronic-buys-implanted-infusion-pump-tech-to-develop-new-type-1-diabetes-treatment

Restraint Factor for the Implantable Insulin Pumps Market

High Expense of Sophisticated Surgical Devices and Procedures Will Limit Market Growth

One of the main factors impeding the Implantable Insulin Pumps market's expansion is the safety risk around implanted infusion pumps. Patients who...

The National Diabetes Audit (NDA) is part of the National Clinical Audit and Patient Outcomes Programme (NCAPOP) which is commissioned by the Healthcare Quality Improvement Partnership (HQIP) and funded and managed by NHS England, in partnership with Diabetes UK. The NDA provides a comprehensive view of diabetes care in England and Wales. It measures the effectiveness of diabetes healthcare against National Institute for Health and Care Excellence (NICE) Clinical Guidelines and NICE Quality Standards. The NDA supports improvement in the quality of diabetes care by enabling participating NHS services and organisations to: Assess local practice against NICE guidelines. Compare their care, and care outcomes, with similar services and organisations, identify gaps or shortfalls that are priorities for improvement, identify and share best practice and provide a comprehensive national picture of diabetes care and outcomes in England and Wales. This data release includes the care process and treatment target measurements for the full 2022-23 audit period (1 January 2022 – 31 March 2023); presented for England primary care and specialist services (hospital-based care), each with its own separate data file. Please note, primary care data for Wales is not yet available. Data for Wales will be made available in January 2024. Data from primary care in England was collected throughout the audit period. Data for specialist services in England is submitted throughout the year with the January 2022 to March 2023 cut of this data being taken in June 2023. Data from Wales was received in November 2023 and will be released in January 2024.

Snapshot img

Artificial Pancreas Market Size 2024-2028

The artificial pancreas market size is forecast to increase by USD 476.7 million, at a CAGR of 19.9% between 2023 and 2028.

The market is experiencing significant growth, driven by the rising global burden of diabetes and increasing awareness programs for diabetes management. The artificial pancreas, an advanced medical device, offers continuous glucose monitoring and insulin delivery, providing better control over diabetes management. The increasing prevalence of diabetes, particularly type 1 and type 2, fuels the demand for these devices. However, the market faces challenges due to stringent regulatory frameworks for artificial pancreas manufacturing. Regulatory bodies, such as the FDA, require rigorous clinical trials and extensive data to ensure safety and efficacy. These requirements increase the time and cost of bringing new products to market. Additionally, the high cost of these devices and limited reimbursement policies pose challenges for patient accessibility. Companies seeking to capitalize on market opportunities must navigate these regulatory hurdles and develop cost-effective solutions to expand their reach.

What will be the Size of the Artificial Pancreas Market during the forecast period?

Explore in-depth regional segment analysis with market size data - historical 2018-2022 and forecasts 2024-2028 - in the full report.
Request Free SampleThe market continues to evolve, driven by advancements in hypoglycemia prevention and glucose management. These systems integrate various components, including continuous glucose monitors (CGMs), insulin delivery systems, and data analytics dashboards, to provide real-time glucose prediction and automated insulin dosing. Patient compliance metrics and algorithm accuracy are crucial factors, with user interface design and bolus insulin calculator features optimized for ease of use. CGM integration methods, remote monitoring capabilities, and device lifespan metrics are also essential considerations. Wearable technology integration and closed-loop algorithms are at the forefront of innovation, enabling seamless data logging and real-time system maintenance. Medical device regulation and patient safety protocols ensure the reliability and long-term efficacy of these systems. Ongoing clinical trials explore new sensor calibration methods, insulin sensitivity factors, and hyperglycemia management techniques. The market's dynamism is further reflected in the integration of smartphone connectivity, battery life optimization, and data analytics capabilities, providing users with valuable insights into their glucose levels and treatment plans.

How is this Artificial Pancreas Industry segmented?

The artificial pancreas industry research report provides comprehensive data (region-wise segment analysis), with forecasts and estimates in 'USD million' for the period 2024-2028, as well as historical data from 2018-2022 for the following segments. TypeThreshold suspend deviceNon-threshold suspend deviceControl to range systemControl to target systemGeographyNorth AmericaUSCanadaEuropeFranceGermanyItalyUKAPACChinaIndiaJapanSouth KoreaRest of World (ROW)

By Type Insights

The threshold suspend device segment is estimated to witness significant growth during the forecast period.Artificial pancreas systems, which include threshold suspend devices, are revolutionizing diabetes management by providing advanced features for improved glycemic control. These systems utilize a closed-loop algorithm to automatically adjust basal insulin delivery based on real-time blood glucose predictions from continuous glucose monitors. Threshold suspend devices, also known as low glucose suspend systems, offer an additional safety feature by temporarily halting insulin delivery when blood glucose levels drop below a certain threshold, preventing hypoglycemia. Patients using these systems must still monitor their blood glucose levels and adhere to proper sensor calibration methods for accurate readings. companies, such as Medtronic Plc, integrate smartphone connectivity and data analytics dashboards to enable remote monitoring and patient compliance tracking. Algorithm accuracy metrics and user interface design are crucial considerations to ensure system reliability and ease of use. Insulin sensitivity factor and patient safety protocols are essential factors in the development of these systems. Wearable technology integration and long-term efficacy studies are ongoing areas of research to enhance system capabilities and improve patient outcomes. Medical device regulation, data logging capabilities, and system maintenance protocols are essential aspects of the market. companies focus on battery life optimization and device lifespan metrics to ensure user convenience and minimize interruptions. Remote monitoring features and cgm integration methods enable healthcare provider

Portugal had the highest prevalence of diabetes in Europe among their adult population with **** percent living with diabetes, as of 2024, Croatia followed with the second-highest share at **** percent. Conversely, Ireland was the country with the lowest prevalence of diabetes in Europe at *** percent. Diabetes-related deaths The highest number of diabetes-related deaths in Europe, at almost ******, was recorded in Germany in 2024. Italy and France followed, with roughly *******and ****** deaths, respectively. Diabetes risk factors in Europe One of the major contributing factors to type 2 diabetes is being overweight or obese. As of 2022, Greece had the highest share of overweight population across Europe, with *****percent. The lack of sports and exercise is also another risk factor. As of 2022, Portugal was the European country with the highest share of people never exercising or engaging in sports, with ** percent.

The European diabetic care devices market, valued at €8.03 billion in 2025, is projected to experience robust growth, driven by rising prevalence of diabetes, an aging population, and increasing awareness of effective disease management. A compound annual growth rate (CAGR) of 6.18% from 2025 to 2033 indicates a significant expansion in market size, reaching an estimated €13.2 billion by 2033. Key growth drivers include technological advancements in continuous glucose monitoring (CGM) systems, offering improved convenience and accuracy compared to traditional self-monitoring blood glucose (SMBG) methods. The increasing adoption of insulin pumps and sophisticated insulin delivery systems further contributes to market expansion. While the market faces restraints like high device costs and the need for continuous patient education, the overall positive trend is fueled by supportive government initiatives and a growing focus on proactive diabetes management, including remote monitoring and telehealth solutions. The market segmentation reveals significant opportunities within CGM, which is projected to outpace SMBG growth due to its enhanced patient experience and improved glycemic control. This is particularly relevant given the increasing prevalence of type 1 diabetes and the associated need for intensive glucose management among younger populations. The competitive landscape is dominated by established players like Dexcom, Medtronic, and Abbott, with a focus on innovation, product differentiation, and strategic partnerships to expand market reach and address unmet needs within specific patient segments. Smaller companies are also actively contributing, driving innovation in areas such as sensor technology and data analytics for personalized diabetes management. Regional variations within Europe exist due to differing healthcare systems, reimbursement policies, and prevalence rates of diabetes. Countries like Germany and the UK are expected to contribute significantly to the overall market growth owing to their large populations and relatively robust healthcare infrastructures. The increasing focus on value-based care and cost-effectiveness in healthcare systems across Europe will also influence the choice of devices and treatment strategies, driving further market segmentation and impacting future growth projections. Recent developments include: Feburary 2024: Dexcom launched real-time CGM solution Dexcom ONE+ in Europe. Dexcom ONE+ is a customisable continuous glucose monitoring solution that can be worn at three different location on the body., June 2022: Cequr, the leader in wearable diabetes technology, released its newest and most innovative insulin delivery device, the Insulin Pen 2.0TM. The pen is small enough to be always worn on the user's body, and it also features a built-in blood glucose meter so that users can track their blood sugar throughout the day.. Notable trends are: The continuous glucose monitoring segment is expected to witness the highest growth rate over the forecast period.

Figures are frequencies except where indicated.

The worksheets include data for all ICBs and GP practices in England within the August 2023 extraction of NDA data (January to June 2023 data). These data undergo further validation processes at the end of each audit year when data from specialist services are added in, at which point the data are considered to comprise the full annual dataset to be used in the annual NDA publications. Data for Local Health Boards (LHBs) in Wales and specialist diabetes services in England are not included in the quarterly publications. Their 2022-23 data (for the full audit period January 2022 to March 2023) will be reported in the full audit period data release and state of the nation report, scheduled for late 2023 and summer 2024 respectively. Disclosure control has been applied to mitigate the risk of patient identification. Zeros are reported, and all numbers are rounded to the nearest 5, unless the number is 1 to 7, in which case it is rounded to ‘5’. This allows for more granular data to be made available, and also for data for all GP practices to be made available. Percentages where the denominator is less than or equal to 20 are not reliable and have therefore not been calculated in this release.